Eduardo Bravo Fernández de Araoz
Vorstandsvorsitzender bei Citryll BV
Ursprung des Netzwerks ersten Grades von Eduardo Bravo Fernández de Araoz
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
INSEAD
115
| College/University | Other Consumer Services | 115 |
28
| Holding Company | Medical Specialties | 28 |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.
11
| Holding Company | Biotechnology | 11 |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
Citryll BV
 Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
Colegio Universitario de Estudios Financieros
7
| College/University | Other Consumer Services | 7 |
| Extinct | Pharmaceuticals: Major | 6 | |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.
5
| Private Company | Biotechnology | 5 |
Alliance for Advanced Therapies
 Alliance for Advanced Therapies Medical/Nursing ServicesHealth Services The Alliance for Advanced Therapies’ mission is to improve the legislative, business and science climate for advanced therapies innovation in Europe. In order to do so, AAT promotes the interests of its members and the advanced therapies sector in Europe. AAT coordinates input to, and exchanges information with relevant European authorities. The Alliance also increases awareness of the sector among all relevant stakeholders, with a special focus on investors. Furthermore, AAT promotes increased funding for the sector from public and private sources.
1
| Subsidiary | Medical/Nursing Services | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Eduardo Bravo Fernández de Araoz
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Université Catholique de Louvain | College/University | Graduate Degree Chairman Graduate Degree Corporate Officer/Principal Graduate Degree | |
| University of Bocconi | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| University of Oxford | College/University | Corporate Officer/Principal Graduate Degree Undergraduate Degree Graduate Degree | |
binx health, inc.
 binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member Director/Board Member Director/Board Member | |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Director of Finance/CFO | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member | |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer Director/Board Member | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Chief Executive Officer | |
| University of St. Gallen | College/University | Undergraduate Degree Masters Business Admin | |
Novavax AB
 Novavax AB Pharmaceuticals: GenericHealth Technology Novavax AB is engaged in research and development of vaccines. Its products include Matrix and AbiSCO. The company was founded by Bror Morein in 1999 and is headquartered in Uppsala, Sweden. | Pharmaceuticals: Generic | Chief Executive Officer Chief Executive Officer | |
| University of Cambridge | College/University | Graduate Degree Graduate Degree | |
SwedenBIO Service AB
 SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| TME PHARMA N.V. | Biotechnology | Director/Board Member Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| MERUS N.V. | Biotechnology | Chairman Director/Board Member | |
| École supérieure d'électricité | College/University | Undergraduate Degree Undergraduate Degree | |
| BI Norwegian Business School | College/University | Graduate Degree Undergraduate Degree | |
Universitaire Ziekenhuizen Leuven
 Universitaire Ziekenhuizen Leuven Hospital/Nursing ManagementHealth Services Universitaire Ziekenhuizen Leuven provides medical services. It offers abdominal surgery, abdominal transplant surgery and coordination, breast centre, cardiac surgery, dentistry, emergency medicine, endocrinology and haematology. The company was founded in 1080 and is headquartered in Leuven, Belgium. | Hospital/Nursing Management | Director/Board Member Corporate Officer/Principal | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor Private Equity Investor | |
| RENEURON GROUP PLC | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Arthur D. Little, Inc.
 Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| Ghent University | College/University | Graduate Degree Doctorate Degree | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
New York State Bar Association
 New York State Bar Association Miscellaneous Commercial ServicesCommercial Services New York State Bar Association is a non-profit organization, which provides legal services and offers a membership program for lawyers. It also publishes an array of books, bar journals, law digest, and State Bar news. The company was founded in 1876 and is headquartered in Alban, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Sciences Po | College/University | Undergraduate Degree Undergraduate Degree | |
Xeltis AG
 Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree | |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree | |
| ESCP Europe Campus Paris | College/University | Undergraduate Degree Graduate Degree | |
| University of Oslo | College/University | Graduate Degree Graduate Degree | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer | |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Affectis Pharmaceuticals AG
 Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| NESTLÉ S.A. | Food: Major Diversified | Corporate Officer/Principal Director/Board Member | |
Altimmune UK Ltd.
 Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Binx Health Ltd.
 Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| LSP Services Deutschland GmbH | Investment Managers | Private Equity Investor President | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| AIR LIQUIDE | Chemicals: Specialty | Sales & Marketing Director/Board Member | |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer |
Statistik
International
| Frankreich | 10 |
| Belgien | 9 |
| Vereinigtes Königreich | 7 |
| Vereinigte Staaten | 6 |
| Schweiz | 6 |
Sektoral
| Health Technology | 22 |
| Consumer Services | 14 |
| Commercial Services | 7 |
| Finance | 6 |
| Health Services | 3 |
Operativ
| Director/Board Member | 616 |
| Corporate Officer/Principal | 178 |
| Chairman | 172 |
| Chief Executive Officer | 115 |
| Independent Dir/Board Member | 89 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Eduardo Bravo Fernández de Araoz
- Unternehmensverbindungen
